Royal Bank Of Canada X4 Pharmaceuticals, Inc Transaction History

Royal Bank Of Canada

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Nov 21, 2025	BUY	$0.24 - $0.81 $3,702 - $12,496	15,428 New	15,428 $3,000
Q1 2025 May 15, 2025	BUY	$0.24 - $0.81 $1,123 - $3,791	4,681 Added 43.56%	15,428 $3,000
Q4 2024 Feb 14, 2025	SELL	$0.28 - $0.82 $2,457 - $7,196	-8,776 Reduced 44.95%	10,747 $8,000
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.86 $2,007 - $3,197	3,718 Added 23.52%	19,523 $13,000
Q2 2024 Aug 14, 2024	BUY	$0.58 - $1.47 $7,507 - $19,027	12,944 Added 452.43%	15,805 $9,000

Q1 2024 Nov 05, 2024	SELL	$0.72 - $1.46 $9,319 - $18,898	-12,944 Reduced 81.9%	2,861 $3,000
Q1 2024 May 15, 2024	SELL	$0.72 - $1.46 $26,251 - $53,231	-36,460 Reduced 92.72%	2,861 $3,000
Q4 2023 Feb 14, 2024	BUY	$0.61 - $0.99 $12,979 - $21,065	21,278 Added 117.93%	39,321 $33,000
Q3 2023 Nov 14, 2023	BUY	$1.03 - $2.02 $8,034 - $15,756	7,800 Added 76.15%	18,043 $19,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $8,399 - $25,505	10,243 New	10,243 $19,000
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.71 $89 - $172	101 New	101 $0
Q3 2021 Nov 15, 2021	SELL	$4.53 - $6.45 $9,349 - $13,312	-2,064 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.49 - $9.56 $13,395 - $19,731	2,064 New	2,064 $13,000

13.9M

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $251M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.